  Rituximab is a chimeric mouse/human monoclonal antibody ( mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching $ 8.58 billion in 2016. Since its initial approval in 1997 , it has improved outcomes in all B-cell malignancies , including diffuse large B-cell lymphoma , follicular lymphoma , and chronic lymphocytic leukemia<disease>. Despite widespread use , most mechanistic data have been gathered from